New Risk • Jul 02
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 73% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr78m free cash flow). Earnings have declined by 28% per year over the past 5 years. Shareholders have been substantially diluted in the past year (73% increase in shares outstanding). Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Market cap is less than US$100m (kr744.4m market cap, or US$76.7m). Board Change • Jun 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 1 highly experienced director. Independent Director Jan-Eric Österlund was the last director to join the board, commencing their role in 2023. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. New Risk • May 20
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Swedish stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr78m free cash flow). Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 28% per year over the past 5 years. Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (kr462.1m market cap, or US$49.2m). Duyuru • Oct 31
Dicot Pharma AB, Annual General Meeting, May 06, 2026 Dicot Pharma AB, Annual General Meeting, May 06, 2026, at 17:00 W. Europe Standard Time. Location: uppsala Sweden New Risk • Oct 23
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Swedish stocks, typically moving 16% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings have declined by 29% per year over the past 5 years. Revenue is less than US$1m. Duyuru • Aug 12
Dicot Pharma AB to Report Q3, 2025 Results on Oct 23, 2025 Dicot Pharma AB announced that they will report Q3, 2025 results on Oct 23, 2025 Duyuru • Jun 26
Dicot Pharma AB Announces Completion of Enrolment in the Ongoing Phase 2a Study Dicot Pharma announced that the enrolment in the ongoing phase 2a study has been completed and that all participants have been dosed. Hence, the company can now conclude that the clinical study will be completed in August. The results will be reported no later than three months thereafter. Dicot Pharma's clinical phase 2a study is fully enrolled and all participants have also been dosed. The company has previously communicated that the study is expected to be completed by mid-2025. As the last participant has now been dosed, the company can conclude that the study will be completed in August 2025, when the last participant's final clinical visit takes place. Once the study is completed, the collected data will be cleaned, the database locked, and a subsequent statistical analysis carried out before results can be reported - a process expected to take two to three months. New Risk • May 30
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Swedish stocks, typically moving 9.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 27% per year over the past 5 years. Shareholders have been substantially diluted in the past year (146% increase in shares outstanding). Revenue is less than US$1m. Minor Risk Share price has been volatile over the past 3 months (9.6% average weekly change). Duyuru • May 28
Dicot Pharma Announces New Findings on Mechanism of Action: "Affects the Sensures Controlling Penile Establishes Dicot Pharma announced that the latest studies on the mechanism of action of their candidate drug LIB-01 show that it affects nerves and vascular structures which interact in creating penile erection. The results can also explain LIB-01's long-lasting effect and emphasize the differentiation to current potency drugs. Dicot Pharma has previously announced that the mechanism of action of the drug candidate LIB-01 differs from currently used potency drugs and thus has the potential to change the paradigm of erectile dysfunction management. The company is characterizing the mechanism of action of LIB-01 and now new results show that LIB-01 affects underlying structures that play a central role in penile erection. A penile erection is a vascular event that occurs in response to sexual stimulation. A dramatic increase in arterial inflow to the penis is essential for an erection and it must be accompanied by a relaxation of the erectile tissue of the penis for the cavernous bodies to fill with blood. Everything is under neural command. By analyzing gene expressions in anatomical structures involved in penile erection, Dicot Pharma has found that LIB-01 affects the nervous and vascular structures that are involved in these processes. These findings differentiate LIB-01 from today's oral potency drugs, the PDE5 inhibitors, which act within the erectile tissue facilitating blood trapping within the penis and thus depend on a sufficient arterial inflow. The fact that LIB-01 affects the underlying structures that control the inflow thus supports the company's goal of also being able to treat men who are not currently helped by PDE5 inhibitors. The change in gene expression may also explain the long-lasting effect of LIB-01 on erectile function. Gene expression is a naturally occurring process whereby information from genes is transferred to the cell's structures and functions, which is crucial for various biological functions, and the effects can be long-lasting. Dicot Pharma is now continuing to characterize the mechanism of action, including studies of specific processes in the body that could cause these gene expression changes. Duyuru • Apr 30
Dicot Pharma AB to Report Q1, 2025 Results on Apr 29, 2025 Dicot Pharma AB announced that they will report Q1, 2025 results on Apr 29, 2025 Recent Insider Transactions Derivative • Apr 04
Independent Director exercised options to buy kr573k worth of stock. On the 31st of March, Michael Zell exercised options to buy 2m shares at a strike price of around kr0.19, costing a total of kr389k. This transaction amounted to 25% of their direct individual holding at the time of the trade. Michael currently holds less than 1% of total shares outstanding. Company insiders have collectively bought kr530k more than they sold, via options and on-market transactions, in the last 12 months. Duyuru • Apr 03
Dicot Pharma AB, Annual General Meeting, May 06, 2025 Dicot Pharma AB, Annual General Meeting, May 06, 2025, at 17:00 W. Europe Standard Time. Location: advokatfirman lindahl, vaksalagatan 10, uppsala, Sweden Duyuru • Feb 05
Dicot Pharma AB Announces the Recruitment of Participants for the Company's Clinical Phase 2a Study is Advancing at a Steady Rate Dicot Pharma AB announced that the recruitment of participants for the company's clinical phase 2a study is advancing at a steady rate, and that half of the planned 140 participants have now been dosed. All participating men have erectile dysfunction and have been in a stable relationship for at least six months. To evaluate the effect of LIB-01 on erectile function, they respond to questions from the standardized questionnaire International Index of Erectile Function. In addition, participants continuously fill out a form of diary after each sexual intercourse. About the phase 2a study: The purpose of the Phase 2a study is to evaluate the efficacy of LIB-01 in men with erectile dysfunction. The study is expected to include 140 participants and is being conducted at six clinics in Sweden (Uppsala, Stockholm, Gothenburg and Linköping), Denmark (Herlev) and the Netherlands (Groningen). Each person will participate in the study for eight weeks after dosing. The trial is double blind and placebo controlled. This means that neither the clinical staff administering the study drug, nor the participants, know which research subjects are receiving LIB-01 and which are receiving placebo. The clinical part of the study is expected to last until mid-2025. This will be followed by a statistical analysis before the results can be reported. Duyuru • Dec 19
Dicot Pharma AB (publ) Announces That the United States Patent and Trademark Office Grants an Additional Patent for Its Efficacy Drug Candidate, LIB-01 Dicot Pharma announced that the United States Patent and Trademark Office (USPTO) has granted an additional patent for its erectile dysfunction drug candidate, LIB-01. The patent is part of a patent family now gaining full approval in the US with protection until 2042. This family is paramount in the company's IP-work and significantly strengthens both product and method protection. The newly granted patents extend both product and method protections in the US until 2042. Dicot Pharma plans to file for corresponding patents in additional geographic regions worldwide. Duyuru • Nov 27
Dicot Pharma AB Receives New Patent in the USA Dicot Pharma AB announced that the US Patent and Trademark Office has granted a new patent covering important steps in the manufacturing of the potency drug candidate LIB-01. Dicot Pharma has received a new patent approved in the US that protects key steps in the manufacture of LIB-01 and is valid until 2042. Dicot Pharma has previously received a Notice of Allowance for a total of three patent applications in the US, and this is the first of these to be formally approved. Recent Insider Transactions • Nov 13
Independent Chairman of the Board recently bought kr58k worth of stock On the 11th of November, Eva Saers bought around 243k shares on-market at roughly kr0.24 per share. This transaction amounted to 42% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Eva has been a buyer over the last 12 months, purchasing a net total of kr141k worth in shares. Duyuru • Nov 08
Dicot Pharma Announces Initiation of Phase 2A Clinical Study After recently receiving approval from authorities, the potency drug developer Dicot Pharma's clinical phase 2a study has now started. The primary objective of the study is to evaluate the efficacy of LIB-01 in patients with erectile dysfunction. Recruitment for the phase 2a study began immediately after the authority's approval and is managed by the company's clinical partner CTC, which is conducting the study. Now the company announces that the study has formally started as the first screening visit has taken place. The primary objective of the phase 2a study is to evaluate LIB-01's efficacy in patients with erectile dysfunction. The study will enroll 140 male participants and will be conducted at six clinics across Sweden, Denmark and the Netherlands. Each patient will participate for eight weeks after initial dosing. The study is double-blind, and placebo controlled, meaning that neither the clinical staff who administer the study drug nor the participants will know which research subjects are receiving LIB-01 and which are receiving placebo. As Dicot Pharma previously announced, the clinical part of the study is expected to last until the middle of 2025. A statistical analysis will then follow before the results can be reported. New Risk • Nov 07
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 185% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). Earnings have declined by 27% per year over the past 5 years. Shareholders have been substantially diluted in the past year (185% increase in shares outstanding). Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (kr409.1m market cap, or US$38.3m). Recent Insider Transactions • Sep 29
Independent Chairman of the Board recently bought kr51k worth of stock On the 25th of September, Eva Saers bought around 320k shares on-market at roughly kr0.16 per share. This transaction increased Eva's direct individual holding by 1x at the time of the trade. This was the largest purchase by an insider in the last 3 months. Eva has been a buyer over the last 12 months, purchasing a net total of kr84k worth in shares. Duyuru • Sep 17
Dicot Pharma AB (publ) Provides an Operational Update Dicot Pharma AB announced that following the successful outcome of Dicot Pharma's rights issue, an operational update is being presented on September 17, 2024. The company will continue to focus on the development of its potency drug candidate, with a phase 2a study set to commence soon. Additionally, the operational plan includes advancing R&D activities, a listing on Nasdaq First North, and initiating preclinical studies for new indications within metabolic diseases. Dicot Pharma's rights issues in August was oversubscribed, and an over-allotment option was exercised, resulting in a total of approximately SEK 135 million before costs to the business. This gives the pharmaceutical company a strong financial position. As the company announced in June, results from animal studies within the framework of LIB-01's research program show that the substance unexpectedly appears to influence several conditions and diseases that are commonly characterized by dysfunction in the body's metabolism. These include conditions such as obesity, diabetes, and high blood pressure. Based on these promising results and the successful outcome of the rights issue, Dicot Pharma's board and management have conducted a strategic review, which now forms the foundation of the operational plan, where the primary focus will continue to be on the clinical development of the potency drug candidate LIB-01. A phase 2a trial is set to begin in the fourth quarter. The company remains on track with its previously communicated timeline regarding all preparations, and the clinical trial application was submitted in July 2024. The placebo-controlled trial, involving approximately 140 patients, aims to demonstrate a statistically significant effect of LIB-01 in improving erectile function in patients with erectile function. The company advances certain R&D activities related to upcoming development phases, including tablet development, scaling up the manufacturing process, and preparations to open an Investigational New Drug Application (IND) in the USA, which is required for conducting clinical trials there. The company will also make other important preparations required for clinical phase 2b. In addition to the development of the potency drug candidateLIB-01, the company's strong financial position allows for the initiation of a preclinical development program in metabolic diseases. A comprehensive market analysis conducted by an external party on behalf of Dicot Pharma has been matched against the company's own available results in metabolic diseases, which in total strongly justifies further research into a number of prioritized indications. In the fourth quarter, the company intends to apply for listing on the Nasdaq First North Growth Market, as it is assessed to support Dicot Pharma's continued development, internationalization, and competitiveness. The listing will enable a broader and more international shareholder base and is anticipated to generate increased interest in the share from stakeholders and analysts. In line with the business strategy for LIB-01, i.e., entering partnerships with larger pharmaceutical companies to finance and further develop the drug for the world market, the strong outcome of the rights issue puts Dicot Pharma in a favorable position. Efforts to engage with potential partners will now be established alongside the phase 2a study and will be carefully managed by the board and management to maximize shareholder value. Duyuru • Jul 25
Dicot Pharma AB to Report Q2, 2024 Results on Aug 23, 2024 Dicot Pharma AB announced that they will report Q2, 2024 results on Aug 23, 2024 Duyuru • Jul 08
Dicot Pharma Announces Clinical Trial Application for Phase 2A Trial Dicot Pharma announced that a clinical trial application for a phase 2a trial with the drug candidate LIB-01, has been submitted. The trial is planned to start in the fourth quarter of 2024 as previously communicated. The trial is fully funded with the amount secured in advance in the announced rights issue that the company intends to carry out in August. Dicot is developing a new potency drug with the aim to treat erectile dysfunction better than existing drugs on the market. With good results from the company's recently completed phase 1 trial, a clinical trial application for a phase 2a trial has now been submitted. It is a so-called "proof of concept", with the main objective of demonstrating that LIB-01 can improve erectile function in patients with erectile dysfunction. The trial, which is placebo-controlled and double-blind, will include approximately 140 participants and will be conducted at clinics in Sweden, Denmark and the Netherlands. The start of the trial is planned for the fourth quarter of 2024, when the first patient is expected to start treatment with LIB-01. Through the commitments obtained in advance in the rights issue that the company intends to carry out in August, the trial is fully financed. Duyuru • Jul 04
Dicot Pharma AB to Report Q3, 2024 Results on Aug 01, 2024 Dicot Pharma AB announced that they will report Q3, 2024 results on Aug 01, 2024 Duyuru • Jul 02
Dicot Pharma AB Completes a Pre-IND Meeting with FDA Dicot Pharma AB announced that the company has held a pre-IND meeting with the US Food and Drug Administration (FDA) and received positive feedback on the development program for the drug candidate LIB-01. This is considered a validation of the quality of the program and is an important step towards an application to include US study centers in future clinical studies and to ensure that the current development plan meets the regulatory requirements for future market approval in the US. Dicot Pharma has recently had its first formal interaction with the US Food and Drug Administration (FDA) via a pre-IND meeting where the agency gave its feedback in writing. An early interaction with FDA is considered valuable to reach a consensus on the structure and objectives of a development program and ultimately secure market approval in the United States. A pre-IND meeting precedes the opening of an Investigational New Drug (IND) application in the United States, which is required to be able to include US study centers in future clinical studies. The main purpose of the meeting was to obtain the Agency's views on the overall development program for LIB-01 in general and the upcoming Phase 2a study in particular. Based on the submitted background material, the FDA provided its views on study design, preclinical development, chemistry, manufacturing, and quality controls. In essence, the company considers that the agency's feedback was positive and helps to ensure that the development program meets the regulatory requirements for the US market. Duyuru • Jun 08
Dicot Pharma AB Develops LIB-01 into A New Potency Drug with Improved Properties Compared to Currently Available Drugs Dicot Pharma AB is developing LIB-01 into a new potency drug with improved properties compared to currently available drugs. New research results on LIB-01 show that the substance appears to influence factors linked to certain metabolic diseases. Based on these research results, the company has submitted a patent application for the treatment of several new indications. Dicot Pharma is developing the potency drug candidate LIB-01 with the aim of offering a treatment that surpasses current drugs, including a long-term effect on erectile function. Within the framework of research on LIB-01, the company has received new results from animal studies showing that the substance unexpectedly appears to influence several conditions and diseases that are commonly characterized by dysfunction in the body's metabolism. These include conditions such as obesity, diabetes and high blood pressure. The company has filed a new patent application to seek protection for the treatment of these indications. Based on these promising results and the currently filed patent application, Dicot's Board of Directors and management will conduct a strategic review during the third quarter of 2024 to determine how these new research results should be taken forward by the company and complement the existing product portfolio in sexual dysfunctions. Duyuru • Apr 24
Dicot AB (publ) Announces Positive Safety and Improved Efficacy Results from Phase 1 Study Dicot AB (publ) completed phase 1 clinical study demonstrates that the company's drug candidate LIB-01 has a very good safety profile, which was the primary objective of the study. In addition to this, the company can deduce an efficacy signal from the study where participants reported an improved erectile function, in some cases beyond 28 days post first dose. The primary objective of Dicot's phase 1 study has been to investigate the safety profile in humans for LIB-01, the company's drug candidate for treatment of erectile dysfunction. In January, Dicot reported good results from the first part where participants received single dosing (a so-called SAD study). Dicot has now locked the database for the final part of the study where the participants were given repeated dosing. Based on today's readout of data, the company can now announce that LIB-01 demonstrated a very good safety profile. No serious adverse effects occurred and there were no dropouts due to adverse events. Only occasional and mild adverse effects were reported in participants receiving LIB-01. Dicot can also see an efficacy signal from the MAD part, in which 24 otherwise healthy men with erectile dysfunction participated and were dosed for three days. An improvement in erectile function has been reported, which was captured by subjective self-report questionnaires and supported by objective measurements using a Viagra®? device. Participants also reported that the improved erectile function lasted for a long time, in some cases the effect remained at the end of the study, i.e., 28 days post first dose. Later in the second quarter, Dicot will be able to provide an in-depth summary of results where the above results will be presented in more detail. The exploratory efficacy measurements will provide important data for the design of the company's planned phase 2a study. The efficacy signal that Dicot has noted must be confirmed in a clinical phase 2a study to provide a definitive "proof-of-concept", i.e. a statistically significant result from a larger group of participants. The study is planned to start in the second half of 2024. Duyuru • Apr 08
Dicot AB (publ) to Report Q1, 2024 Results on May 06, 2024 Dicot AB (publ) announced that they will report Q1, 2024 results on May 06, 2024 Duyuru • Mar 12
Dicot AB (publ) Announces Recruitment Completed in Dicot's Phase 1 Trial Dicot AB (publ) announced that the recruitment to the final part of its phase 1 study is completed. The study is thus proceeding according to the previously communicated timeline and the results are expected to be announced during the second quarter. Dicot's phase 1 study, aiming at investigating the safety profile in humans, started in August 2023 and consists of two parts: SAD (single dose) and MAD (multiple doses). The study is placebo-controlled and double-blind, meaning that some participants receive LIB-01 and some receive placebo, and neither the participant nor the physician knows which of the two was dosed. In January 2024, Dicot announced the first results from the SAD, which showed that the drug candidate LIB-01 has a very good safety profile. There were no serious side effects, nor were dose increases limited by any side effects. The MAD includes some 25 participants divided into different dose groups where the dosage is increased between the different groups. Dicot has now recruited the last participant, which means that the study is progressing according to plan. Overall results are expected to be announced in the second quarter of 2024, as previously communicated by the company. New Risk • Feb 28
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr45m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr45m free cash flow). Share price has been highly volatile over the past 3 months (19% average weekly change). Earnings have declined by 29% per year over the past 5 years. Shareholders have been substantially diluted in the past year (87% increase in shares outstanding). Revenue is less than US$1m (kr228k revenue, or US$22k). Minor Risk Market cap is less than US$100m (kr151.2m market cap, or US$14.6m). Duyuru • Jan 29
Dicot AB (publ) to Report Fiscal Year 2023 Results on Feb 26, 2024 Dicot AB (publ) announced that they will report fiscal year 2023 results on Feb 26, 2024 Duyuru • Jan 23
Dicot AB (publ) Presents Positive Results from the First Part of its Phase 1 Clinical Study Dicot presents positive results from the first part of its phase 1 clinical study showing that LIB-01 has a very good safety profile. There were no serious adverse effects. The results also show that the drug is well absorbed in the body, which puts the company in a strong position for clinical phase 2. The primary objective of Dicot's phase 1 study is to investigate the safety of the potency drug candidate LIB-01 in humans. The study is double-blind and placebo-controlled and consists of two parts: SAD and MAD. The SAD part studies increasing single doses of LIB-01 regarding safety parameters such as adverse effects as well as how well the drug is absorbed in the body. In the MAD part, the same assessments are done, but with repeated dosing. The company announces the first overall results from the SAD part, showing a very good safety profile. The company announced the first overall results from the MAD, the second and final part of the phase 1 study, will be published in the second quarter of 2024. Duyuru • Jan 11
Dicot Applies for Patent Covering New Manufacturing Technology Dicot has applied for a patent covering a novel technology to manufacture the starting material for its potency drug candidate. It concerns a custom-designed approach in cell cultivation developed in partnership with Uppsala University. In 2022, Dicot started a research project with Uppsala University and W. Szafer Institute of Botany to investigate whether the starting material for the drug candidate LIB-01 could be produced by using plant cells grown in cultures; an established technology for large-scale commercial production of many medicinal substances originally derived from nature. According to the company, the project - in which a custom-designed method is used to produce cells and grow them - has been successful in demonstrating at a laboratory scale that the technology works. Therefore, the project will now progress to larger-scale testing. At the same time, a patent application is submitted to the Swedish Patent and Registration Office to protect this way of producing the starting material. The action will be followed by further patent applications on several other relevant markets. Duyuru • Dec 15
Dicot AB (publ) Announces Partial Results from Phase 1 Trial to Be Presented Early Next Year Dicot AB (publ) concluded the clinical part of the SAD, earlier than initially planned. Consequently, the company will be able to report these results already in the January-to-February transition. Results from the second and final part of the phase 1 trial are expected to be communicated in the second quarter of next year, as previously announced. Dicot's phase 1 trial of the potency drug candidate LIB-01 is placebo-controlled and double-blinded, with the primary objective of investigating the safety profile in humans. The trial started in August of this year and consists of two parts: SAD (Single Ascending Dose) and MAD (Multiple Ascending Dose). On December 14, 2023, the last participant in the SAD completed his final clinic visit, signifying that all participants have been dosed and undergone subsequent safety follow-up. Now, a period of data cleaning and analysis remains. Dicot previously communicated that the trial results were expected to be presented during spring 2024. However, as the company now has successfully gathered all necessary data in the SAD earlier than originally planned, these results can be communicated already in the January-February month transition. Simultaneously, the MAD is progressing as scheduled, with the first group of participants having received doses. Results from the MAD are expected to be communicated in the second quarter of 2024, as previously communicated. Recent Insider Transactions Derivative • Nov 20
Director exercised options to buy kr169k worth of stock. On the 14th of November, Michael Zell exercised options to buy 1m shares at a strike price of around kr0.086, costing a total of kr90k. This transaction amounted to 15% of their direct individual holding at the time of the trade. Since March 2023, Michael's direct individual holding has increased from 6.09m shares to 7.14m. Company insiders have collectively bought kr374k more than they sold, via options and on-market transactions, in the last 12 months. New Risk • Nov 17
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Swedish stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 30% per year over the past 5 years. Shareholders have been substantially diluted in the past year (356% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (kr101.3m market cap, or US$9.59m). Minor Risk Share price has been volatile over the past 3 months (11% average weekly change). Duyuru • Oct 29
Dicot AB, Annual General Meeting, May 06, 2024 Dicot AB, Annual General Meeting, May 06, 2024. Agenda: To consider determination of fees and other compensation for the board and its committees, divided between the chairman and other board members; to consider determination of fees for auditors; to consider election of board members and chairman of the board; to consider election of auditors; and to consider Principles for the Nomination committee's composition and work ahead of the 2025 AGM. Duyuru • Oct 25
Dicot AB Initiates Repeated Dosing in Phase I Study Dicot AB recently entered phase I with its drug candidate LIB-01, where the first step is to test single dosing on healthy volunteers. In parallel, the company is now starting the second part of the study, testing repeated dosing of the candidate. The first results from the study are expected in the spring. Duyuru • Oct 20
The Second Part of Dicot's Phase 1 Study Starts on October 20, 2023 In August, Dicot's phase 1 study was initiated, with single dosing of the participants. Concurrently, the second part of the study starts October 20, 2023 where safety of LIB-01 is now being studied with repeated dosing. Dicot's first clinical study in humans with the potency drug candidate LIB-01 started in August and is in full swing. Initially, participants were administered a single dose, called Single Ascending Dose (SAD). Now, in parallel, the study is moving into next part where new participants receive repeated dosing, also called Multiple Ascending Dose (MAD). Today, the first screening visit takes place to identify participants for the MAD part's first dose group. The screening means that applicants are examined based on a variety of selection criteria for participation in the study. As the company previously announced, this is a placebo-controlled phase 1 clinical trial with the primary objective to evaluate the safety profile of LIB-01 in humans. The entire study is double-blinded, which means that some participants receive LIB-01 and some receive a placebo, and that neither the participant nor the physician knows which of the two was dosed. Duyuru • Oct 02
Dicot AB to Report Q3, 2023 Results on Oct 31, 2023 Dicot AB announced that they will report Q3, 2023 results on Oct 31, 2023 Duyuru • Sep 27
Dicot AB Applies for International Patent Protection Dicot has submitted an international patent application through the Patent Cooperation Treaty, enabling for protection in 157 countries. The patent application covers drug substances in development and their manufacturing methods. Dicot has filed a patent application through the Patent Cooperation Treaty (PCT) covering 157 countries, encompassing all key markets. The application includes relevant drug substances currently in development, their composition, and their manufacturing methods. Granted patents will provide comprehensive protection for Dicot's drug candidate, LIB-01. But the application itself already offers indirect protection in all these markets throughout the process. A PCT application is initially reviewed by a patent authority selected by the company. The authority's opinion then forms the basis for further handling by the respective authorities responsible for the various markets the company decides to pursue. The PCT process significantly streamlines the procedure and makes it more cost-effective, and it is used by most leading pharmaceutical companies. Dicot has chosen the European Patent Office as the first reviewing authority, which also allows for a shorter lead time regarding granted patents in Europe. Although the USA is included in the PCT application, Dicot has also submitted the same patent application directly to the United States Patent and Trademark Office through a fast-track program called the Patent Prosecution Highway (PPH). This is done with the aim of expediting the grant of a patent in what the company considers a key market. The same patent application was previously submitted to the Swedish Patent and Registration Office, enabling the PPH application strategy. Duyuru • Sep 05
Dicot AB Announces First Participants Dosed in Phase 1 Trial Dicot announced that the first study participants have been dosed in the company's clinical phase 1 trial. Dicot has recently started the first clinical trial with its potency drug candidate LIB-01. The primary objective of the study is to evaluate the safety of LIB-01 and consists of two parts: single dosing and repeated dosing. The recruitment of healthy participants for the first part of the study, the single dosing, started immediately after approval from the authorities and the first participants have been dosed. The trial is performed at the University Hospital in Uppsala, where the company's partner CTC has its clinic. The single-dose part of the study involves around 50 participants, divided into different dose groups and where the doses are gradually increased in subsequent groups. After dosing, participants are admitted for a period of three days during which frequent safety assessments are conducted, including blood sample collection, blood pressure monitoring, and ECG, all of which are standard procedures in this type of first-in-human study. The single dosing will be followed by the second part of the study where repeated doses are given to each of the participants. The entire phase 1 trial is double blinded and placebo-controlled, which means that some participants receive LIB-01 and some receive placebo and that neither the participant nor the investigator know who receives LIB-01 and who receives placebo. Duyuru • Aug 30
Dicot AB Applies for US Patent Dicot announced that a patent application has been submitted to the US Patent Office. The application covers the new oral drug formulation of the candidate LIB-01 which is now used in the ongoing phase 1 clinical study. Dicot submitted a patent application to the United States Patent and Trademark Office. It concerns patententing a method of formulating LIB-01 that enables an oral intake of the active substance. The new oral formulation was developed in 2022 and is now being used in the company's clinical phase 1 study. Dicot announced last year that the company had submitted a new patent application covering new production methods and chemical compounds. Now Dicot is converting yet another of the company's trade secrets into a patent. The application is a so-called provisional patent application that aims to get an approved patent in the United States. Shortly, this will be followed by an application to the Swedish Patent and Registration Office where the application can later be expanded to other markets. Duyuru • Aug 25
Dicot AB (publ) Announces Clinical Phase 1 Study Starts Dicot AB announced that it is the formal start of Dicot's clinical phase 1 study with the drug candidate LIB-01 as the first screening visit is being performed. The study is a placebo-controlled trial with the primary objective to evaluate the safety profile in humans. Last week, Dicot received approval from the relevant authorities to start a clinical phase 1 trial. Dicot's partner CTC, which will conduct the study, began recruiting participants immediately. Since all other preparations were completed, the study can start now, just over a week after the approval. It commences with the first of two screening visits to identify participants for the study's first dose group. Screening is the process where research applicants are examined and selected based on a variety of study specific criteria. As Dicot previously announced, this is a placebo-controlled phase 1 clinical trial with the primary objective to evaluating LIB-01's safety profile in humans. The trial is double-blind, meaning that neither clinic staff who administer the study drug, nor participants, know who is receiving LIB-01 and who is receiving placebo. Duyuru • Aug 15
Dicot AB Receives Approval to Start Phase 1 Clinical Trial Dicot AB announced that the Swedish Medical Products Agency has granted permission to start clinical phase 1 trial with the drug candidate LIB-01. It is a placebo-controlled trial with primary objective to evaluate the safety profile in humans. Dicot's first-in-human study of the potency drug candidate LIB-01 has now received permission to start from the Swedish Medical Products Agency. Approval from the Ethics Review Authority has also been obtained and other preparations are complete. Screening of participants and dosing of the first dose group will start shortly. It is a placebo-controlled phase 1 clinical trial where the primary objective is to evaluate LIB-01's safety profile in humans. The trial evaluates the safety following increasing doses of LIB-01 in healthy participants, both as a single ascending dose (SAD) and multiple ascending doses (MAD). Duyuru • Jul 26
Dicot AB to Report Q2, 2023 Results on Aug 24, 2023 Dicot AB announced that they will report Q2, 2023 results on Aug 24, 2023 Recent Insider Transactions Derivative • Jun 21
Director exercised options to buy kr194k worth of stock. On the 15th of June, Michael Zell exercised options to buy 1m shares at a strike price of around kr0.11, costing a total of kr115k. This transaction amounted to 17% of their direct individual holding at the time of the trade. Since March 2023, Michael has owned 6.09m shares directly. Company insiders have collectively bought kr181k more than they sold, via options and on-market transactions, in the last 12 months. New Risk • Jun 20
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Swedish stocks, typically moving 18% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr31m free cash flow). Share price has been highly volatile over the past 3 months (18% average weekly change). Earnings have declined by 40% per year over the past 5 years. Shareholders have been substantially diluted in the past year (325% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (kr88.4m market cap, or US$8.16m). Duyuru • Jun 02
Dicot AB (publ) Submits Application to Start Clinical Phase 1 Trial Dicot announced that an application to start clinical trial with the potency drug candidate LIB-01, has been submitted to the Swedish Medical Products Agency. Dicot is developing a new potency drug with the aim to treat erectile dysfunction and premature ejaculation better than existing drugs. The company has previously announced that the clinical phase 1 trial with LIB-01 is planned to start in August. The company has submitted the application to the Swedish Medical Products Agency to start a phase 1 clinical trial. This study is a "first-in-human" trial, and it will be the first time that LIB-01 is tested in humans. The main objective with the trial is to evaluate the safety and tolerability of LIB-01 in humans. Duyuru • May 23
Dicot to Seek Initiation of a Phase I Clinical Trial for the Drug Candidate Lib-01 In August, Dicot is expected to take its biggest step as a development company with the planned initiation of a phase I clinical trial for the drug candidate LIB-01. Over the past quarter, the company has worked hard to strengthen both its team and finances in preparation for the study start. Duyuru • May 18
Dicot's Study Drug Arrives in Sweden In preparation for Dicot's phase 1 clinical trial, the study drug to be used has now been manufactured by Thermo Fisher Scientific and arrived in Sweden. In February, the contract manufacturer Thermo Fisher Scientific began producing the study drug to be used when Dicot enters clinical trials with its potency drug candidate, which is planned for August this year. The manufacturing, done according to Good Manufacturing Practice, has now been completed and the study drug has arrived in Sweden. Study drug with active substance as well as matching placebo have been manufactured, in accordance with the requirements for conducting a clinical phase 1 trial. Now Uppsala-based CTC AB - the contract research organization that will conduct the study - takes over the responsibility for the study drug, to prepare and dispense it for use in the clinical trial. Duyuru • May 05
Dicot AB Appoints Mats Silvander as New chief technical officer Dicot AB appointed Mats Silvander, PhD, as its new chief technical officer. Silvander is set to begin his new position on 14 August 2023. In this newly created CTO position, aimed at strengthening the company's internal capacity in strategic areas, Silvander will lead and develop Dicot's Supply Chain and Intellectual Property work. Silvander brings over 20 years of industry experience in areas such as pharmaceutical manufacturing, supplier management, patent work, and team development. He has worked previously with Novavax AB, BioGaia, Paragon Nordic, and Quinnova Pharmaceuticals. Duyuru • Feb 18
Dicot AB Study Results Presented at European Society for Sexual Medicine Dicot AB presented the latest study of the mechanism of action of LIB-01 at the European Society for Sexual Medicine's annual congress in Rotterdam. The study shows that the mechanism of action differs from today's most common potency drugs, PDE5 inhibitors, and that LIB-01 may thus represent a completely new generation of potency drugs. The European Society for Sexual Medicine(ESSM) is a leading scientific organization in sexual medicine. The annual congress is now underway, bringing together prominent researchers and doctors in the field from all over the world. Today, Dicot's latest study of the mechanism of action of LIB-01 was presented, that is, how the drug affects underlying processes so that the desired effect occurs. Dicot has previously announced the results of the ex vivo study, which show that the mechanism of action differs from today's most common potency drugs, PDE5 inhibitors such as Viagra, and that LIB-01 may thus represent a completely new generation of potency drugs. The study results were selected by ESSM's scientific council to be presented at the annual congress in 2023. Duyuru • Jan 29
Dicot AB to Report Fiscal Year 2022 Results on Feb 27, 2023 Dicot AB announced that they will report fiscal year 2022 results on Feb 27, 2023 Board Change • Nov 16
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Director Fredrik Buch was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Duyuru • Nov 16
Dicot AB Announces That It's Latest Study of the Mechanism of Action of LIB-01 Assumed to Be the Next Generation of Potency Drugs Dicot AB announced that it's latest study of the mechanism of action of LIB-01, how the drug affects the body to achieve the desired effect, shows that it differentiates from today's potency drugs. This means that LIB-01 can be assumed to represent a new generation of potency drugs. Dicot is developing a modern potency drug to treat erectile dysfunction and premature ejaculation better than existing medicines. As part of the long-term development work, studies are underway to map LIB-01's mechanism of action - that is, how the drug affects underlying processes in the body so that the desired effect occurs. Results from a recent ex vivo study show that the mechanism of action of LIB-01 differentiates from today's potency drugs such as e.g., Viagra. These are significant results as today's potency drugs, with their mechanism of action, do not work optimally for all patients whereof approximately 35% do not have sufficient effect and many report unwanted side effects. Duyuru • Nov 15
Dicot AB Announces Successful First Regulatory Meeting for LIB-01 Dicot AB announced that the first regulatory meeting for LIB-01 prior to an application to start clinical trials has been conducted. This was the first of two planned scientific advisory meetings with the Swedish Medical Products Agency, with the purpose of anchoring the scientific background documentation for a clinical trial application. Dicot is developing a new potency drug that aims to become the first choice for the treatment of erectile dysfunction and premature ejaculation. The company plans to start clinical trials with the drug candidate LIB-01 in mid-2023. As part of the preparation to enter clinical phase, the company has now conducted the first of two planned scientific advisory meetings with the Swedish Medical Products Agency, with the purpose of anchoring the scientific background documentation for a clinical trial application. The scientific advice concerned central parts regarding both manufacturing and pharmacology. The next advisory meeting will focus on the design of the planned clinical trial as well as the toxicological package. Duyuru • Oct 18
Dicot AB to Report Q3, 2022 Results on Nov 15, 2022 Dicot AB announced that they will report Q3, 2022 results on Nov 15, 2022 Duyuru • Oct 12
Dicot AB Reports Good Results from Preclinical Toxicology Studies Dicot AB reports that the preclinical toxicology studies that are now being conducted, so far show that the drug candidate LIB-01 has a good safety profile. Dicot is now conducting several toxicology studies within the framework of the preclinical program with the drug candidate LIB-01. Studies of the toxicity of a drug candidate are a necessary and important part of the authorities' approval process for start of clinical studies in humans. Dicot has performed studies with a subcutaneous formulation and now the first toxicology study with an oral formulation has been conducted. LIB-01 has so far shown to be well tolerated with a good safety profile and no signs of adverse effects have been seen in the animal studies. A number of studies remain to be conducted before the company's toxicology program is complete. Duyuru • Jul 28
Dicot AB to Report Q2, 2022 Results on Aug 25, 2022 Dicot AB announced that they will report Q2, 2022 results on Aug 25, 2022 Duyuru • Jun 11
Dicot AB Moves Forward with New Patent Application Dicot AB is developing the drug candidate LIB-01, a potency drug to better treat erectile dysfunction and premature ejaculation. The company announced that it is now moving forward with a new patent application in order to extend the patent protection around the company's drug candidate until at least 2042. Dicot is developing a new potency drug that aims to be the first choice for the treatment of erectile dysfunction and premature ejaculation. At the beginning of 2022, Dicot announced that several new patent opportunities were identified and that they would be protected as trade secrets, in order to convert these into patents at the right point of time. The goal of the strategy is to ensure the longest possible market exclusivity and revenue opportunity for LIB-01 and thereby the shareholder value. Dicot announced that the company will proceed with one of these trade secrets and that a new patent application is being prepared. The purpose is to patent both new manufacturing methods and intermediates (various chemical compounds) during the manufacture of the drug substance in Dicot's product candidate LIB-01. The patent application will be submitted after the summer. Patents provide 20 years of market exclusivity from the time the application is submitted. Reported Earnings • May 08
First quarter 2022 earnings released First quarter 2022 results: Net loss: kr9.35m (loss widened 10% from 1Q 2021). Board Change • Apr 27
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Board Member Per-Goran Gillberg was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Duyuru • Apr 20
Dicot AB Appoints Charlotta Gauffin as Chief Scientific Officer Charlotta Gauffin PhD has been hired as Chief Scientific Officer at Dicot starting July 11 with the task of leading the development of the company's potency drug. Dr. Gauffin has over 20 years of experience in drug development, of which more than 15 years in clinical development. The Uppsala based pharmaceutical company Dicot has previously announced that it intends to broaden and strengthen the management for the next phase where focus will be on clinical studies, business development, and partnerships with international pharmaceutical companies. An important part of this is the appointment of a Chief Scientific Officer (CSO). The recruitment has been finalised and Dr. Charlotta Gauffin will be Dicot's new CSO from July 11. Dr. Charlotta Gauffin has over 20 years of experience in drug development, from for example Biovitrum, Medivir, and Galderma. For the past 15 years, she has been responsible for clinical development and project management, as well as Program Director at Quintiles, and most recently Head of Clinical Operations at LIDDS AB. Duyuru • Apr 08
Dicot AB Announces Board Changes The Nomination Committee of Dicot AB proposes that Fredrik Buch and Michael Zell are elected as new ordinary Board members of the Board of Dicot AB at the Annual General Meeting on May 24, 2022. bba Florin-Robertsson and Claes Post have declined re-election. The Nomination Committee proposes Eva Sjökvist Saers as Chairman of the Board. Fredrik Buch is a Medical Doctor and Ph.D with a degree from the University of Gothenburg. Fredrik's professional activities include medical research and clinical activities, medical R&D in the pharmaceutical industry as well as fund management and venture capital/investments. Fredrik has been Head of SEB Läkemedelsfonder, partner at HealthCap, partner and founder of Brilleon Capital and has been active as a venture consultant for Karolinska Investment Fund. Fredrik Buch has extensive experience from Board work and is currently active in the Boards of e.g. Lobsor Holding AB, Intrance Medical System Inc/Intrance Holding AB, Cytovac A/S, Pila B and Acarix AB. Michael has been appointed chairman of the Swedish Ship Mortgage Fund by the government. During 2014-2018, he was president of the Royal Örlogsmannasällskapet - Swedish Marine Academy. Michael Zell has been a shareholder in Dicot AB since the company's listing in 2018 and has participated in all issues. Duyuru • Apr 03
Dicot AB Announces CEO Changes Elin Trampe is the new CEO of the Dicot starting April 1, 2022. Elin brings important experiences from e.g. business development, international partnerships and operational excellence. Elin's focus as new CEO will be to focus on taking the company into the next phase. Elin Trampe succeeds Göran Beijer, who remains in the company as a consultant. Elin Trampe was hired by the company as COO and Deputy CEO in September 2021 and succeeds Göran Beijer as CEO. Elin Trampe's main task as CEO will be to take the company into the next phase in the best way, where the focus will be on clinical studies, business development and partnerships with international pharmaceutical companies. Duyuru • Dec 08
Dicot Announces That the Results of Dicot's Drug Candidate Will Be Presented At the European Society for Sexual Medicine Dicot announced that the results of Dicot's drug candidate will be presented at the European Society for Sexual Medicine's (ESSM) annual congress in Rotterdam in February 2022. ESSM is the leading scientific society for sexual medicine and the annual congress in February brings together prominent researchers and doctors from around the world. Dicot and Pelvipharm have sent in an abstract with results from animal studies demonstrating the long-term effect of LIB-01. Dicot now announced that ESSM's Scientific Council, after reviewing all abstracts submitted to the congress, selected Dicot's abstract to be presented orally at the annual congress. As previously reported, Dicot is collaborating with the French contract laboratory Pelvipharm, world leading in the field of sexual dysfunctions. Studies with Dicot's drug candidate LIB-01 have, as previously reported, demonstrated effect on erectile function, tested in both healthy rats and in animals with a disease picture. Duyuru • Feb 10
Dicot AB Announces Election of Eva Sjökvist Saers as the Chairman of Board, At the Extraordinary General Meeting Held on February 9, 2021 Dicot AB announced election of Dr Eva Sjökvist Saers as the new Chairman of the Board of the company, at the Extraordinary General Meeting held on February 9, 2021. She thereby replaces Lars Jonsson, who remains as a member of the board. Dr Sjökvist Saers's 25-year career in life science began immediately after her dissertation in pharmaceutical science when she was recruited to a management role at Astra. There she was, among other things, head of the pharmaceutical research unit at Astra Pain Control. After the merger of Astra and Zeneca, Eva worked with R&D-related strategies for the new company. As CEO of APL, she took the company from being part of the state pharmacy monopoly to a competitive independent company. In a couple of years, sales almost tripled and went from SEK 500 million to SEK 1.3 billion. During the years 2008-2016, Eva was the first ever female chairman of the board of The Pharmacy Society, which dates to the 17th century and is a modern organization for professionals. Eva currently works as a professional board member in several life science companies such as Recipharm and Bluefish Pharmaceuticals. She is also chairman of Vinnova's strategic innovation program Swelife. Duyuru • Feb 06
Dicot AB (publ) Broadens Testing of the Drug Candidate LIB-01 Dicot AB (publ) broadens the testing of the drug candidate LIB-01: conducts studies of premature ejaculation. The main focus for the potencdrug developer Dicot has so far been on studyiying the effect on erectile dysfunction in its drug candidate LIB-01. In accordance with the
company's overall strategy, testing is now being broadened. Therefore, studies of premature ejaculation have started together with the world
-leading contract research organisation that has participated in preclinical testing of several renowned compounds in this field. Dicot's goal for its drug candidate LIB-01 (formerly Libiguin) is to be the leading treatment for erectile dysfunction and premature ejaculation. So far, research has revolved mostly around erectile dysfunction and this work is progressing in accordance with the company's development plan. Testing is now being extended by including premature ejaculation to assess the effect of the drug candidate in animal models relevant to this indication. The first study is already initiated and aims to evaluate the effect of LIB-01 treatment on ejaculation in anesthetized rats. The results will form the basis for the next step when the company enters more advanced models where the animals' behaviour will be studied in more detail. Results are expected to be announced later in 2021. The studies are carried out in collaboration with Pelvipharm SAS, a world-leading preclinical contract Research Organisation specializing in the evaluation of sexual dysfunctions and which has collaborated with several leading big pharmaceutical companies in this field. Premature ejaculation is lone of the most common form of sexual dysfunction. Epidemiological studies indicate that 18-30% of all men are burdened by premature ejaculation, that's about every fourth man. The global market was estimated at approximately USD 1.5 billion in 2018 and is expected to grow even more in the coming years. Is New 90 Day High Low • Feb 02
New 90-day low: kr0.94 The company is down 19% from its price of kr1.17 on 03 November 2020. The Swedish market is up 14% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 9.0% over the same period. Duyuru • Jan 29
Dicot Initiates Toxicology Studies Before Applying for Clinical Trials Dicot launches a toxicology program for the drug candidate LIB-01. The program runs until the autumn and will form the basis for an application for clinical trials on humans. In accordance with Dicot's development plan, the company will move on to toxicological studies that are expected to be completed in the autumn of 2021. It is toxicology that determines the extent of possible side effects in the body. The studies aim at evaluating the extent to which the active substance in the drug candidate LIB-01 (formerly Libiguin) is toxic to the user. Since all chemicals are considered to have a certain toxic effect if the dose is high enough, the study also establishes the maximum dose that can be used in future studies. Dicot's toxicological program consists of one study in rodents and one in non-rodents, which is a requirement of the medical products agencies. Rat and dog are the most common animal models in this type of study. The program began in December with a fourteen-day study - a so-called dose range finding study - in rats. Analysis of the results is currently underway. It will be followed by the same type of study in dogs, thereafter by experiments in both animal models with dosing for 28 days. The studies are carried out in collaboration with certified Clinical Research Organizations (CRO) with extensive experience of regulatory studies and accredited to perform these according to the standard Good Laboratory Practice. Is New 90 Day High Low • Jan 12
New 90-day low: kr0.99 The company is down 31% from its price of kr1.43 on 14 October 2020. The Swedish market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is flat over the same period. Is New 90 Day High Low • Dec 22
New 90-day low: kr1.06 The company is down 41% from its price of kr1.79 on 22 September 2020. The Swedish market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 7.0% over the same period. Duyuru • Nov 27
Dicot Ordinary Shares to Be Deleted from Other OTC Dicot AB.’s Ordinary Shares (Sweden) will be deleted from Other OTC effective November 27, 2020, due to Inactive Security. Is New 90 Day High Low • Nov 17
New 90-day low: kr1.11 The company is down 42% from its price of kr1.93 on 19 August 2020. The Swedish market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 7.0% over the same period. Is New 90 Day High Low • Oct 20
New 90-day low: kr1.33 The company is down 11% from its price of kr1.50 on 22 July 2020. The Swedish market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 12% over the same period. Duyuru • Oct 13
Dicot AB Continues Studies with Pelvipharm to Generate Knowledge About Treatment Times, Doses and Libiguin's® Mechanism of Action Dicot has conducted the first study in collaboration with Pelvipharm SAS with tests in a model for erectile function in normal rats. Satisfactory results showed that treatment with Dicot's substance Libiguin® has a dose-dependent effect in these animals. Likewise, Sildenafil (Viagra), the reference compound routinely used in this model, displayed the expected effect on erectile functions of normal rats. In this first study, the experimental animals were dosed in a similar way that was originally used in folk medicine use in Madagascar and which was also used in the previous preliminary animal experiments conducted by Dicot. The animals were treated with Libiguin® once a day for three days and 24 hours after the last dose, during day four, the effect on erectile function was measured. In a new set of experiments planned together with Pelvipharm, additional testing in normal rats will be performed to investigate how Libiguin® should be administered (treatment time in relation to measuring effect on erectile function) to give the best effect. Also more doses will be evaluated to better understand the dose-exposure-effect relationship and the effect following long-term treatment of Libiguin®. After optimization of treatment conditions in normal animals, Libiguin® will be further tested in some of Pelvipharm's established disease models where rats with eg diabetes or a cardiovascular disease will be used because it is known that erectile function is impaired in these disease states. Libiguin® will be tested in one or more of these models. In parallel, Dicot and Pelvipharm continue the work of investigating Libiguins® mechanism of action with a number of ongoing and planned trials. Each individual trial provides additional knowledge to continue the mapping of how Libiguin® exerts its effect on erection. Duyuru • Oct 07
Dicot AB Announces That Sustainable Supply of Raw Material Important to Dicot Dicot AB together with its partner in South Africa, Parceval Ltd, has initiated a partnership with the BioInnovation Africa (BIA) project of the Deutsche Gesellschaft für Internationale Zusammenarbeit (GIZ) to ensure the long-term supply of raw material for Dicot's drug candidate. The aim of the BioInnovation Africa project, which is funded by the German Federal Ministry of Economic Cooperation and Development (BMZ), is to promote sustainable and mutually beneficial business partnerships between Europe and Africa by ensuring high ethical, social and environmental standards in the use of African natural resources. By entering into this partnership with BIA, Dicot will be supported in mapping the distribution of the trees growing in South Africa, which are used for the raw material of Dicot's drug candidate Libiguin®. The partnership also provides an opportunity to assess moving the process of extracting the raw material to South Africa in order to get closer to the raw material source. This together facilitates the conservation of biodiversity, ensures a sustainable supply and creates new jobs in South Africa in alignment with the goals in Agenda 2030. The project will run until mid-2022. Duyuru • Sep 12
Dicot AB to Report Q2, 2020 Results on Aug 27, 2020 Dicot AB announced that they will report Q2, 2020 results on Aug 27, 2020 Duyuru • Aug 31
Dicot AB to Report Q3, 2020 Results on Nov 23, 2020 Dicot AB announced that they will report Q3, 2020 results on Nov 23, 2020